Swiss pharma giant Novartis AG is harnessing the power of Zurich-based Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat Covid-19 infection.

Full-service healthcare communications marketing agency MicroMass Communications launched the podcast series Intersect, which tells stories of behavioral science in action.

Allele Biotechnology and Pharmaceuticals filed lawsuits against Regeneron Pharmaceuticals, as well as Pfizer and Germany’s BioNTech, claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their Covid-19 treatments.

Javelin Biotech announced a three-year collaboration with Pfizer to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules.

Johnson & Johnson announced a major milestone as the company launched a large-scale, international Phase III trial for the Covid-19 vaccine candidate JNJ-78436735.

Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.

EVERSANA launched ACTICS by EVERSANA, a technology-enabled solution to optimize end-to-end commercial success for life science companies.

GlaxoSmithKline opened a new $13 million research hub in London focused on artificial intelligence.

Blue Knight, a program created in partnership with Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA), chose seven startups from J&J’s global JLABS incubator network to participate in the fight against the world’s current Covid-19 pandemic and future ones.

According to a new study by Worldwide Partners, the effect that Covid-19 is having on digital health adoption is set to be transformative. The survey that was conducted shows technology is playing a crucial and growing role in mitigating the healthcare crisis, especially via telehealth.